| E.1 Medical condition or disease under investigation |
| E.1.1 | Medical condition(s) being investigated |
| NTRK fusion cancers previously treated with a TRK inhibitor |
|
| E.1.1.1 | Medical condition in easily understood language |
| Solid tumors of all type, including primary CNS tumors |
|
| E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
| MedDRA Classification |
| E.1.2 Medical condition or disease under investigation |
| E.1.2 | Version | 21.0 |
| E.1.2 | Level | LLT |
| E.1.2 | Classification code | 10049516 |
| E.1.2 | Term | Malignant tumor |
| E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| E.1.2 Medical condition or disease under investigation |
| E.1.2 | Version | 21.0 |
| E.1.2 | Level | PT |
| E.1.2 | Classification code | 10007958 |
| E.1.2 | Term | Central nervous system neoplasm |
| E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| E.1.3 | Condition being studied is a rare disease | Yes |
| E.2 Objective of the trial |
| E.2.1 | Main objective of the trial |
| To determine the recommended dose for further study of oral selitrectinib in 2 patient groups with previously treated neurotrophic tyrosine receptor kinase (NTRK) fusion cancers defined as age 12 years and older and age < 12 years. |
|
| E.2.2 | Secondary objectives of the trial |
• To characterize the pharmacokinetic (PK) properties of selitrectinib
• To characterize the safety and tolerability of selitrectinib.
• To assess objective response rate (ORR) according to best response by
Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
as determined by Investigator.
• To assess ORR according to best response by Response Assessment in
Neuro Oncology (RANO), as determined by Investigator, in patients with
primary central nervous system (CNS) malignancies with NTRK fusion. |
|
| E.2.3 | Trial contains a sub-study | No |
| E.3 | Principal inclusion criteria |
1. Ability to understand and the willingness to sign a written informed
consent. A signed informed consent must be obtained prior to any studyspecific
procedures. Parent/guardian of child or adolescent subjects has
the ability to understand, agree to, and sign the study Informed Consent
Form and applicable Pediatric Assent Form before initiation of any
protocol related procedures; subject has the ability to give assent, as
applicable, at the time of parental/guardian consent.
2. Advanced solid tumor for which, in the opinion of the Investigator, no
other standard therapy offers greater benefit.
3. A solid tumor diagnosis in the setting of:
a. a documented NTRK fusion and a clinical history of relapse following a
response to a prior TRK inhibitor
b. a documented NTRK fusion unresponsive to a prior TRK inhibitor
c. a documented NTRK fusion and a clinical history of intolerance to a
prior TRK inhibitor
A list of agents with known TRK inhibitor activity is provided in Appendix
A. Other agents not listed may also be considered upon Sponsor review.
NTRK (NTRK1, NTRK2, and NTRK3) gene fusions will be identified in a
CLIA-certified (or equivalently-accredited diagnostic) laboratory. If such
a report cannot be provided, other available certifications/accreditations
are required and need to be documented. Acceptable methods of
detection of NTRK fusion include next-generation sequencing (NGS),
fluorescence in situ hybridization (FISH), real-time polymerase chain
reaction (RT-PCR) with the following documented in a written report:
• For NGS, the report indicates that a fusion was detected between an
NTRK gene (NTRK1, NTRK2, or NTRK3) and a specific partner gene.
• For FISH, the report indicates that a probe mapping to an NTRK gene
(NTRK1, NTRK2, or NTRK3) and/or a probe mapping to a specific partner
gene were found to be colocalized by microscopy.
• For RT-PCR, the report indicates that a pair of primers targeting an
NTRK gene (NTRK1, NTRK2, or NTRK3) on one end and a specific partner
gene on the other end amplified a detectable target.
If enrolling a patient based on the pan-TRK IHC result, documentation of
NTRK fusion must be provided using NGS. If enrolling a patient based on
FISH result, additional documentation of NTRK fusion using NGS is
preferred.
Exception: Patients with infantile fibrosarcoma (IFS) or congenital
mesoblastic nephroma (CMN) may be enrolled based on confirmation of
an ETV6 aberration without an identified partner gene (for example,
patients may have been diagnosed with IFS or CMN based on an ETV6+
FISH test without identifying [or testing] for NTRK3).
4. Performance Status: Eastern Cooperative Oncology Group (ECOG)
score ≤ 2 (in adults), Karnofsky Performance Status (KPS) ≥ 50% (age
≥ 16 years) or Lansky Performance Score (LPS) ≥ 50% (age < 16
years).
5. Evaluable and/or measurable disease by RECIST v1.1, RANO or
International Neuroblastoma Response Criteria (INRC).
6. Life expectancy of at least 3 months.
7. At least 1 month of age.
8. Tissue submission. Samples from 2 time points are required if
available.
a. Tumor sample obtained after patient progression on therapy with last
kinase inhibitor with anti TRK activity prior to consenting for this trial. A
fresh biopsy in this setting is preferred if it can be safely obtained or this
may be an archived sample. See Section 7.5.4 for specifics.
b. Archived tumor tissue sample obtained prior to when patient started
on the first anti-TRK therapy.
If the site has tissue from both time points, but will only provide tissue
from 1 time point, the sample obtained post-progression on the last anti-
TRK therapy is preferred. If no tumor tissue samples from either time
point are available, the patient may still be eligible with Sponsor
approval.
9. Adequate hematologic function, for patients without known or
suspected bone marrow involvement, defined as in Section 4.1
10. Adequate hepatic function defined as:
a. Aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) ≤ 2.5 × upper limit of normal (ULN) or ≤ 5 × ULN if in the setting
of liver metastases
b. Total bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN if in the setting of liver
metastases or Gilbert's disease; patients with higher total bilirubin levels
due to Gilbert's disease or hepatic metastases may be enrolled with
Sponsor approval |
|
| E.4 | Principal exclusion criteria |
1. Prior exposure to second generation TRK inhibitor (e.g. selitrectinib,
repotrectinib (TPX-0005), taletrectinib (DS-6501b/AB-106)). Exception
is in case patient presented intolerance to the second generation TRK
inhibitor agent and the duration of exposure was less than 28 days. No
previous treatment with selitrectinib is allowed.
2. If received recent therapy, evidence of moderate-severe/uncontrolled
toxicities that in the opinion of the investigator are limiting of
subsequent therapy or unstable organ dysfunction due to previous
treatment.
3. Concurrent treatment with a strong CYP3A4 inhibitor or inducer (refer
to Appendix B), consumption of grapefruit juice or Seville orange, or
drugs associated with QT prolongation. The Investigator should review
concomitant medications with their site pharmacist as the list can
change frequently.
4. Clinically significant active cardiovascular disease or history of
myocardial infarction within 3 months prior to planned start of
selitrectinib, cardiomyopathy; current or known history within the past 6
months of prolonged QT interval corrected for heart rate (QTc interval) >
480 milliseconds. If there is a known explanation for a limited period of
a prolonged QT interval (i.e., a medication known to cause prolonged QT
interval was administered and has since been discontinued with clearly
documented normal QT interval thereafter), that subject may be
enrolled. If subject suffers from congestive heart failure, with onset
more than 3 months prior to planned start of selitrectinib, then New York
Heart Association (NYHA) classification should be functional capacity I
at maximum (APPENDIX J).
5. Major surgery within 7 days of enrollment. Catheter placement,
endoscopic procedures, and dental surgery are not considered major
surgery.
6. Uncontrolled systemic bacterial, fungal or viral infection. Infections
treated with a stable dose of antimicrobial therapy for at least 7 days are
allowed. Prophylactic antibiotics are allowed.
7. Pregnancy or lactation.
8. Known hypersensitivity to any of the components of the
investigational agent, selitrectinib or Ora Sweet® SF and OraPlus®, for
patients who will take the selitrectinib suspension. Please refer to
Appendix G for the complete list of ingredients for Ora-Sweet® SF and
Ora-Plus®.
9. Known history of human immunodeficiency virus (HIV). Refer to
Section 4.2 Exclusion Criteria of the protocol for additional details.
10. Hepatitis B (HBV) or C (HCV) infection. Refer to Section 4.2 Exclusion
Criteria of the protocol for additional details.
11. Any malabsorption condition.
12. Substance abuse, medical, psychological, or social conditions that
may interfere with the patient's participation in the study or evaluation
of the study results. |
|
| E.5 End points |
| E.5.1 | Primary end point(s) |
MTD and/or recommended dose for further study of selitrectinib in
patients age 12 years and older and age < 12 years. |
|
| E.5.1.1 | Timepoint(s) of evaluation of this end point |
Every cohort from baseline until disease progression, unacceptable
toxicity, patient's withdrawal of consent, or death. |
|
| E.5.2 | Secondary end point(s) |
• Incidence, severity, and duration of AEs, including all, serious, and
those considered treatment related.
• Changes from baseline in clinical safety laboratory values and vital
signs.
• ORR as determined by the Investigator, in patients with a documented
NTRK fusion cancer previously treated with a TRK inhibitor using RECIST
v1.1 for solid tumors.
• ORR as determined by the treating Investigator using RANO in patients
with primary CNS malignancies,.
• To characterize the PK properties of selitrectinib (Cmax, AUC(0-10),
AUC(0-12) for BID dosing, and AUC(0-24) for QD dosing, if applicable. |
|
| E.5.2.1 | Timepoint(s) of evaluation of this end point |
PK properties of selitrectinib will be determined between C1D6 and C1D8
EORTC QLQ-C30 and EQ-5D or PedsQL should be conducted at the same
cycle visits as the disease assessment. |
|
| E.6 and E.7 Scope of the trial |
| E.6 | Scope of the trial |
| E.6.1 | Diagnosis | No |
| E.6.2 | Prophylaxis | No |
| E.6.3 | Therapy | Yes |
| E.6.4 | Safety | Yes |
| E.6.5 | Efficacy | Yes |
| E.6.6 | Pharmacokinetic | Yes |
| E.6.7 | Pharmacodynamic | No |
| E.6.8 | Bioequivalence | No |
| E.6.9 | Dose response | Yes |
| E.6.10 | Pharmacogenetic | Yes |
| E.6.11 | Pharmacogenomic | No |
| E.6.12 | Pharmacoeconomic | No |
| E.6.13 | Others | No |
| E.7 | Trial type and phase |
| E.7.1 | Human pharmacology (Phase I) | Yes |
| E.7.1.1 | First administration to humans | No |
| E.7.1.2 | Bioequivalence study | No |
| E.7.1.3 | Other | Yes |
| E.7.1.3.1 | Other trial type description |
|
| E.7.2 | Therapeutic exploratory (Phase II) | Yes |
| E.7.3 | Therapeutic confirmatory (Phase III) | No |
| E.7.4 | Therapeutic use (Phase IV) | No |
| E.8 Design of the trial |
| E.8.1 | Controlled | No |
| E.8.1.1 | Randomised | No |
| E.8.1.2 | Open | Yes |
| E.8.1.3 | Single blind | No |
| E.8.1.4 | Double blind | No |
| E.8.1.5 | Parallel group | No |
| E.8.1.6 | Cross over | No |
| E.8.1.7 | Other | No |
| E.8.2 | Comparator of controlled trial |
| E.8.2.1 | Other medicinal product(s) | No |
| E.8.2.2 | Placebo | No |
| E.8.2.3 | Other | No |
| E.8.3 |
The trial involves single site in the Member State concerned
| No |
| E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
| E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
| E.8.5 | The trial involves multiple Member States | Yes |
| E.8.5.1 | Number of sites anticipated in the EEA | 10 |
| E.8.6 Trial involving sites outside the EEA |
| E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
| E.8.6.2 | Trial being conducted completely outside of the EEA | No |
| E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
| Australia |
| Canada |
| Hong Kong |
| Korea, Republic of |
| Singapore |
| United States |
| France |
| Spain |
| Germany |
| Italy |
| Belgium |
| Denmark |
| Ireland |
| United Kingdom |
|
| E.8.7 | Trial has a data monitoring committee | No |
| E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
| E.8.9 Initial estimate of the duration of the trial |
| E.8.9.1 | In the Member State concerned years | 2 |
| E.8.9.1 | In the Member State concerned months | 3 |
| E.8.9.1 | In the Member State concerned days | 1 |
| E.8.9.2 | In all countries concerned by the trial years | 5 |
| E.8.9.2 | In all countries concerned by the trial months | 4 |
| E.8.9.2 | In all countries concerned by the trial days | 21 |
Print
